Content uploaded by Ana Pedro
Author content
All content in this area was uploaded by Ana Pedro on Sep 02, 2023
Content may be subject to copyright.
A Review of The Role of Hemoglobin in Different types of Cancer
ISSN 2753-8176 (online)
Ana Pedro1
1Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK
Keywords:
1. Corresponding author: info@gwyntwr1386.com
A role for haemoglobin in cancer diagnosis in general is supported by a good number of
publications. A previous work indicated the possibility of a direct relationship between the
hemoglobin level and not only the early stages of cancer, but also the chemically induced
precancerous condition (1). Interestingly, in patients with a diagnosis of primary lung, colorectal,
breast or liver cancer, higher post-diagnosis haemoglobin change regardless of the baseline
haemoglobin levels and the direction of changes associates with a significantly shorter survival (2).
Here we summarize, the results of our findings in what concerns proteomics analyzis of
several different cancer patient samples and of cancer cell lines and cancer models for
several different hemoglobin subunits and variants.
Breast cancer
Preliminary data of our lab have showed that we have identified a biomarker for early stage ER+
breast cancer, HCG1745306 isoform CRA-a (3).Additional published data from our lab shows
that hemoglobin subunit alpha (HBA1), which was found to be present in urine samples of
patients with early breast cancer (BC) (4), also presents very high mascot scores in plasma
samples of patients with early BC. The mascot scores, however, drop in the plasma of
patients with locally advanced BC and of patients with certain metastatic patterns. Also,
HBA1 is not significantly present in the primary BC tumor tissues, although bone metastases,
show a high score for this protein. Hemoglobin subunit beta (HBB), which was found to
increase breast cancer cells aggressiveness and associates with poor prognosis (5), also
presents very high mascot scores in plasma samples of patients with early BC. The mascot
scores, however, drop in the plasma of patients with locally advanced BC, but are significant
in the primary BC tissues what allows us to think might be secreted by the tumor. Bone
metastases, also show a high score for this protein (6).
Melanoma
We found that the mascot scores, for hemoglobin subunits alpha (HBA), delta (HBD) and
gamma (HBG) increase considerably for the melanoma patients, both non-metastatic and
metastatic, in comparison to healthy patients (controls). Also, melanoma patients with
undetected metastasis or that will develop metastasis in the future might express HBB and a
fragment of hemoglobin epsilon (HBE1) (7).
Pancreatic cancer
We found out that normal mouse pancreas tissue conditioned media (CM) does not show any
hemoglobin subtype. However, PanIn CM may show good amount of HBB and vestigial amounts
of HBA. By other side, AsPc1 CM shows good amounts of both types of hemoglobin subunits.
The remaining samples only show hemoglobin subunit alpha: BXPC3 CM shows vestigial
amounts, HPAF2 CM vestigial amounts or a good amount, MiaPaca2 CM a good amount,
PAN02 CM a good amount or nothing and PANC1 CM nothing. These results suggest that in
pancreatic cancer, similarly to what might happen with other cancer types (5), HBB might play a
role, in particular in the initial stages of pancreatic cancer. HBA might have a role in established
PC.
Colorectal cancer
We found out that pre-malignant tissues such as human colon epithelial cells express different
hemoglobin subunits. In particular, HBB which possibly is involved in tumor progression (5)
compared with pre-malignant colon tissue presents a raised score in primary tumor cells lines.
Curiously, when P53 is overexpressed the score goes down again. The score is bigger again at
stage III cell line, SW620. We can see moreover, HBB scores raises when comparing the
primary tumor with the p53 knock-out cell line. By adding vitamin D or by adding vitamin D and
P53 overexpression the scores for HBB go down again. We found out that HBE is only
expressed by the primary tumor and by the P53 knock-out cell line where there is an huge
increase in HBE score compared with the primary tumor. HBG is expressed in the pre-malignant
colon tissue and in the primary cancer cell lines which show an increased score in comparison to
the pre-malignant tissues. Moreover, the scores for this hemoglobin are slightly raised in p53
knockout and decrease with adding vitamin D. The human alpha globin gene cluster is located
on chromosome 16. The alpha-2 and alpha-1 coding sequences are identical. Two alpha chains
plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total
hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with fetal
hemoglobin makes up the remaining 3% of adult hemoglobin. HBA is expressed by pre-
malignant tissues and its score raises in the primary cancer tissues. P53 overexpression and in
stage III tissues there are slight decreases in this protein score. This protein scores raises in the
p53 knockout in comparison to the primary cancer, however adding vitamin D or vitaminD+p53
overexpression do slightly increase the scores for this protein. In conclusion, all hemoglobin
subunits (gamma 2, beta and alpha) are expressed in pre-malignant colon tissues except
hemoglobin subunit epsilon. All hemoglobins scores are raised and hemoglobin epsilon gets
expressed in the primary cancer. P53 overexpression causes a decrease in the scores of HBB
and HBA. In stage III there are decreases in the scores of HBB and HBA. P53 knockout causes
increases in all proteins scores. Adding vitamin D or vitaminD+P53 overexpression seem to
provoke unclear effects in these hemoglobolin subunits scores. Pre-malignant tissues may
express hemoglobin subunits to levels which do not cause harm. However, raised expression or
appearance of these proteins in the primary tumors may prompt survival and proliferation of
tumor cells (5). However, overexpression of P53 may hinder cancer cell proliferation. In stage III
there are decreases in the scores of HBB and HBA, perhaps this explains the efficacy of
adjuvant chemotherapy at this stage (8).
Gastric cancer
We analyzed by proteomics the secretion of different hemoglobin by different gastric cancer cell
lines derived from primary tumor tissues or lymph node metastases or stage IV tumors in cell
culture. We found out that, HBG-2 is present in both primary cancer (SNU1) and lymph node
(LN) metastases (HGC27) . From primary cancer to LN metastases, HBG-2 score raises
considerably. HGC27 also shows the presence of HBB and HBA. Curiously, stage IV cells
(SNU16) do not show any types of hemoglobins (9).
Prostate cancer
By proteomics analysis of cell CM precipitates, derived from cell culture of prostate cancer cells
lines such as PC3, DU145, Vcap, and LNcap, we found that all these cell lines secrete HBB with
a range of different scores, being that LNcap (lymph node metastasis) only secretes HBB and
with a low score. Both PC3 (bone metastasis, negative to androgen receptor) and DU145 (brain
metastasis) secrete HBA with a low score. Moreover, Vcap (bone metastasis, wild type (WT)
androgen receptor), additionally expresses HBD with a level 2 score. Finally, PC3 also secretes
hemoglobin gamma-2 (HG2) with a low score (5-8)
Lung cancer
We analyzed by proteomic analysis, the precipitates derived from CM of different lung cancer
cell lines, all NSCLC and also derived from the culture of a bone metastases from lung cancer
sample. In what concerns, adenocarcinomas, HBB and HBA scores raise from primary cancer
to lymph node (LN) metastases. HBG2 may appear with a NS (non-significant) score in primary
cancer, but becomes significant in LN metastases. In other NSLCs types, HBB score raises from
primary cancer to LN metastases. Finally, bone metastases, show a spectacular raise on HBB
and HBA, appears HBD with a very strong score, also HBG1 and HBE and HBZ (hemoglobin
zeta) is non-significant (10).
Head and Neck cancer
We analyzed by proteomics the CM precipitates of two different samples of head and neck
cancer samples culture, M2 and M9. We found that HBB and HBD are consistently found in
both samples with significant Mascot scores (11).
Bone cancer
Cell lines such as 143B and SKES1 express HBB, HBA and HBG2, cell lines such as SAOS,
additionally express HBD and U2OS does not express HBG2, but expresses a different HBD
variant (E9PFT6) (12).
Children’s cancers
We analyzed by proteomic analysis, the precipitates derived from CM of IMR5, SKNBe2a and
CCG9911 cell lines. All these cells lines express HBA and HBB. Only neuroblastoma cell lines
express HBE. HBG2 is expressed in SKNBe2a and CCG9911 cell lines (13).
Acute leukemias
We found out that HBA, Mascot scores are raised in leukemia samples, while HBB Mascot
scores are lower in leukemia samples. Also, HBD only is present in control samples (14).
For a summary, please, see Table 1.
Table 1: Distribution of different types of haemoglobins accordingly to different cancer types. Mets- metastasis, CRC- colorectal cancer, LN-
lymph node, AR- androgen receptor negative, WT – wild-type androgen receptor
References
1. Taylor A, Pollack, MA. Hemoglobin Level and Tumor Growth. Cancer Research (1942)
2. BMC Cancer. 2013 Jul 10;13:340. doi: 10.1186/1471-2407-13-340.Post-diagnosis hemoglobin change
associates with overall survival of mulple malignancies - results from a 14-year hospital-based cohort of
lung, breast, colorectal, and liver cancers. Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, Chen G, Xing
J, Yang H.
3. Tucker R, Pedro A. Blood-derived non-extracellular vesicle proteins as potenal biomarkers for the
diagnosis of early ER+ breast cancer and detecon of lymph node involvement. Version
3. F1000Res. 2018 Mar 6 [revised 2018 May 10];7:283. doi: 10.12688/f1000research.14129.3.
eCollecon 2018.
4. Beretov J, Wasinger VC,Millar EK, Schwartz P, Graham PH, Li Y.Proteomic Analysis of Urine to Idenfy
Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. PLoS One. 2015 Nov
6;10(11):e0141876. doi: 10.1371/journal.pone.0141876.
5. Non-convenonal role of haemoglobin beta in breast malignancy. Brish Journal of Cancer (2017) 117,
994–1006 | doi: 10.1038/bjc.2017.247. Marco Ponze
6. Pedro A (2022). Hemoglobin as a biomarker for breast cancer ISSN 2753-8176 (online) (DOI:
10.13140/RG.2.2.25461.65764)
7. Pedro A (2022). Hemoglobin as a biomarker for melanoma - short report DOI:
10.13140/RG.2.2.32520.29445, ISSN 2753-8176 (online)
Hemoglobin subtype CRA-a HBA HBB HBD HBG HBF HBE HBZ
Early breast cancer Increased Increased Increased
Locally advanced breast cancer Decreased Decreased
Breast cancer certain mets Decreased Increased
Bone metastases Increased Increased
Non-mets melanoma Present Present Present
Mets melanoma Increased Increased? Increased Increased Increased Increased?
Initial pancreatic cancer Increased
Established pancreatic cancer Increased
Pre-malignant CRC Present Present Present
Primary CRC Increased Increased Increased Increased
Stage III CRC Decreased Increased
Primary gastric cancer Present
Gastric cancer LN mets Increased Increased Increased
Gastric cancer stage IV
Prostate cancer LN mets Present
Prostate cancer brain mets Present Present
Prostate cancer bone mets AR- Present Present Present
Prostate cancer bone mets WT Present Present
Present Present
Lung cancer adenocarcinoma LN mets Increased Increased Present
Present
Other lung cancers LN mets Increased
Lung cancer bone mets Increased Increased Present Present Present Present
Head and Neck cancer Present Present
Bone cancer Present Present Present
Children cancers Present Present
Children cancers Neuroblastoma Present Present Present
Acute Leukemia Increased Decreased
Acute Leukemia control Present
Lung cancer adenocarcinoma 1o
Other lung cancers 1o
8. Pedro A (2022). Hemoglobin in colorectal cancer (DOI: 10.13140/RG.2.2.32515.99363, ISSN 2753-8176
(online))
9. Pedro A (2023).Hemoglobin in gastric cancer (ISSN 2753-8176 (online), DOI:10.1101/202291v1 , Small
report
10. Pedro A (2023).Hemoglobin in Lung Cancer - Short report (ISSN 2753-8176 (online), DOI:
10.13140/RG.2.2.30186.59842
11.Pedro A (2023).Hemoglobin in Head and Neck cancer - Short report (ISSN 2753-8176 (online), DOI:
10.13140/RG.2.2.16792.67846
12. Pedro A (2023).Hemoglobin and osteoblasts markers in bone cancer, ISSN 2753-8176 (online), DOI:
10.13140/RG.2.2.14509.05606
13. Pedro A (2023).Hemoglobin and Children’s cancers - Brief Report, DOI: 10.13140/RG.2.2.21321.52325,
ISSN 2753-8176 (online)
14. Pedro A (2023).Hemoglobin in Acute Leukemias - Brief report , ISSN 2753-8176 (online)